论文部分内容阅读
目的 :探讨前列腺素E1治疗重型病毒性肝炎的临床疗效。方法 :6 0例重型病毒性肝炎患者随机分成治疗组 30例对照组 30例 ,对照组给予常规护肝 ,退黄及对症治疗 ,治疗组在给予常规对症治疗基础上 ,加用前列腺素E1(PGE1)静滴。观察疗效和不良反应。结果 :治疗组有效率为 76 .6 7% ,对照组为 4 6 .6 7%。治疗组胆红素降低明显优于对照组 ,肝肾综合症发生率明显低于对照组 (P <0 .0 5 ) ,不良反应轻微。结论 :PGE1可作为治疗重型病毒性肝炎的有效药物
Objective: To investigate the clinical efficacy of prostaglandin E1 in the treatment of severe viral hepatitis. Methods: Sixty patients with severe viral hepatitis were randomly divided into treatment group (n = 30) and control group (n = 30). The control group was treated with conventional liver protection, yellowing treatment and symptomatic treatment. The treatment group was given conventional symptomatic treatment with prostaglandin E1 PGE1) intravenous infusion. To observe the efficacy and adverse reactions. Results: The effective rate of the treatment group was 76.6% and that of the control group was 46.76%. The treatment group bilirubin was significantly better than the control group, the incidence of hepatorenal syndrome was significantly lower than the control group (P <0.05), mild adverse reactions. Conclusion: PGE1 can be used as an effective drug in the treatment of severe viral hepatitis